Skip to main content

Artificial pancreas systems

19-05-2023 | Type 1 diabetes | News

Over 60s with type 1 diabetes show trust in Cambridge hybrid closed-loop system

The use of the Cambridge hybrid closed-loop insulin delivery system by older adults with type 1 diabetes mellitus is associated with “improved quality of life,” says an international team of researchers.

30-03-2023 | Artificial pancreas systems | News

Virtual closed-loop initiation success in very young children

The Tandem Control-IQ system delivers improved glucose control versus standard care in children with type 1 diabetes aged between 2 and 6 years and can be initiated virtually, report researchers.

30-11-2022 | Artificial pancreas systems | News

Real-world data show reduced diabetes burden in young closed-loop users

Real-world use of hybrid closed-loop insulin delivery is associated with improved glycemic control and sleep quality, as well as reduced fear of hypoglycemia in children and young people with type 1 diabetes, shows a UK study.

23-09-2022 | EASD 2022 | Conference coverage | News

Bolus timing requires more attention in people using advanced technologies for type 1 diabetes

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

Illustration showing CGM communicating with Insulin Pump

20-09-2022 | EASD 2022 | Conference coverage | News

​​​​​​​Fully closed-loop control boosts TIR in insulin-treated type 2 diabetes

A fully closed-loop insulin delivery system markedly increases time in range for people with insulin-treated type 2 diabetes, shows a small randomized crossover trial.

07-09-2022 | Pathogenesis | News

CLOuD: Early and sustained closed-loop therapy does not stave off beta-cell decline

Starting young people on closed-loop insulin delivery within 21 days after type 1 diabetes diagnosis does not slow the decline in their C-peptide levels over the next 12 months, report the CLOuD investigators.

07-09-2022 | Artificial pancreas systems | News

AHCL system benefits people with poorly controlled type 1 diabetes

Use of the MiniMed 780G advanced hybrid closed-loop system leads to greater reductions in glycated hemoglobin levels than conventional treatment in people with poorly controlled type 1 diabetes, ADAPT study data show.

06-09-2022 | Artificial pancreas systems | News

Closed-loop control may support neurodevelopment in adolescents

Improved glycemic control with hybrid closed-loop insulin delivery may facilitate the typical neurodevelopmental changes that occur during adolescence for those with type 1 diabetes, suggests a proof-of-concept trial.